106 related articles for article (PubMed ID: 7710267)
1. In vitro and in vivo anti-herpes viral activities and biological properties of CV-araU.
Ashida N; Sakata S; Kano F; Nishitani M; Watanabe Y; Machida H
Antiviral Res; 1994 Dec; 25(3-4):179-84. PubMed ID: 7710267
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds.
Machida H; Sakata S
Antiviral Res; 1984 Jun; 4(3):135-41. PubMed ID: 6089657
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oral treatment with BV-araU against cutaneous infection with herpes simplex type 1 in shaved mice.
Machida H; Ijichi K; Takezawa J
Antiviral Res; 1992 Feb; 17(2):133-43. PubMed ID: 1554238
[TBL] [Abstract][Full Text] [Related]
4. Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys.
Soike K; Huang JL; Tu JI; Stouffer B; Mitroka JG; Swerdel M; Olsen S; Bonner DP; Tuomari AV; Field AK
J Infect Dis; 1992 Apr; 165(4):732-6. PubMed ID: 1313071
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats.
Ashida N; Ijichi K; Watanabe Y; Machida H
Biochem Pharmacol; 1993 Dec; 46(12):2201-7. PubMed ID: 8274153
[TBL] [Abstract][Full Text] [Related]
6. Effects of various nucleosides on antiviral activity and metabolism of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus types 1 and 2.
Suzutani T; Machida H; Sakuma T; Azuma M
Antimicrob Agents Chemother; 1988 Oct; 32(10):1547-51. PubMed ID: 2847634
[TBL] [Abstract][Full Text] [Related]
7. Effect of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus type 1 infection in immunosuppressed mice.
Ijichi K; Ashida N; Machida H
Antimicrob Agents Chemother; 1990 Dec; 34(12):2431-3. PubMed ID: 1965108
[TBL] [Abstract][Full Text] [Related]
8. Retinal toxicity and ocular kinetics of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rabbits.
Mochizuki K; Torisaki M; Yamashita Y; Komatsu M; Tanahashi T; Ijichi K; Machida H
Graefes Arch Clin Exp Ophthalmol; 1994 Aug; 232(8):503-8. PubMed ID: 7926887
[TBL] [Abstract][Full Text] [Related]
9. Antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against thymidine kinase negative strains of varicella-zoster virus.
Kawai H; Yoshida I; Suzutani T
Microbiol Immunol; 1993; 37(11):877-82. PubMed ID: 8295566
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antiviral efficacies of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (brovavir) and acyclovir against herpes simplex virus type 1 infections in mice.
Machida H; Ikeda T; Ashida N
Antiviral Res; 1990 Aug; 14(2):99-107. PubMed ID: 2177319
[TBL] [Abstract][Full Text] [Related]
11. Metabolic fate of [3H]1-beta-D-arabinofuranosyl-5-[(E)-2-bromovinyl]uracil in herpes simplex virus type 1-infected cells.
Ashida N; Sakata S; Machida H
Microbiol Immunol; 1997; 41(12):957-64. PubMed ID: 9492181
[TBL] [Abstract][Full Text] [Related]
12. Different antiviral potencies of BV-araU and related nucleoside analogues against herpes simplex virus type 1 in human cell lines and Vero cells.
Machida H; Nishitani M; Suzutani T; Hayashi K
Microbiol Immunol; 1991; 35(11):963-73. PubMed ID: 1663576
[TBL] [Abstract][Full Text] [Related]
13. Topical treatment with BV-araU of immunosuppressed and immunocompetent shaved mice cutaneously infected with herpes simplex virus type 1.
Ijichi K; Ashida N; Varia S; Machida H
Antiviral Res; 1993 May; 21(1):47-57. PubMed ID: 8391248
[TBL] [Abstract][Full Text] [Related]
14. Effect of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (brovavir) on experimental infections in mice with herpes simplex virus type 1 strains of different degrees of virulence.
Machida H; Takezawa J
Antimicrob Agents Chemother; 1990 May; 34(5):691-6. PubMed ID: 2163240
[TBL] [Abstract][Full Text] [Related]
15. Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines.
Machida H; Ijichi K; Ohta A; Honda M; Niimura M
Microbiol Immunol; 1990; 34(11):959-65. PubMed ID: 1965323
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Yokota T; Konno K; Mori S; Shigeta S; Kumagai M; Watanabe Y; Machida H
Mol Pharmacol; 1989 Aug; 36(2):312-6. PubMed ID: 2549386
[TBL] [Abstract][Full Text] [Related]
17. In vitro antiherpesviral activity of 5-alkyl derivatives of 1-beta-D-arabinofuranosyluracil.
Machida H; Sakata S; Kuninaka A; Yoshino H; Nakayama C; Saneyoshi M
Antimicrob Agents Chemother; 1979 Aug; 16(2):158-63. PubMed ID: 485126
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) in the treatment of experimental herpes simplex virus type 1 keratitis in rabbits: comparison with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR).
Töpke H; Gräf M; Wutzler P; Herrmann G; Reefschläger J
Antiviral Res; 1988 Jul; 9(4):273-80. PubMed ID: 3202622
[TBL] [Abstract][Full Text] [Related]
19. A radioimmunoassay for the new antiviral agent 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Jagoda E; Ogan M; Stouffer B; Tsay HM; Turabi N; Mantha S; Yost F; Tu JI
Ther Drug Monit; 1992 Dec; 14(6):499-508. PubMed ID: 1485373
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship between (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BV-araU, V-araU) in inhibition of Epstein-Barr virus replication.
Lin JC; Reefschläger J; Herrmann G; Pagano JS
Antiviral Res; 1992 Jan; 17(1):43-52. PubMed ID: 1310582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
